biotech
- Home
- biotech
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated
Read MorePublic
Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
In May 2023, diversified digital health company Vitura Health (ASX: VIT) announced a joint venture with Canadian psychedelic company PharmAla Biotech, giving birth to its Melbourne-based psychedelics arm, Cortexa. Providing an update on the 50-50 venture, the Company has noted an “Australian first” win. Its MDMA bulk GMP (good manufacturing practice) Active Pharmaceutical Ingredient (API)
Read MorePublic
Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
PANDAS and PANS are debilitating conditions characterised by distressing symptoms, ranging from rage to signs of obsessive compulsive disorder.
Read MorePublic
Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers. The definitive sale agreement of its
Read MorePublic
Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
A blue chip denotes the cream of the crop—the most put-together, high-quality company or share. So one can only imagine that naming your company Bluechiip would entail high expectations. And high pressure. Two years ago, advanced sampling management company Bluechiip (ASX: BCT) announced that it would directly market its Bluechiip-Enabled products to end-users, concentrating especially
Read MorePublic
Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%
Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose and with limited treatment options. Thanks to a new study conducted by the Garvan Institute of Medical Research, however, a drug developed by biotech company Pharmaxis (ASX: PXS) could increase patient survival rates by 35%.
Read MorePublic
